Ceftriaxona Finlay may be available in the countries listed below.
Ceftriaxone is reported as an ingredient of Ceftriaxona Finlay in the following countries:
International Drug Name Search
Tilarin may be available in the countries listed below.
Nedocromil sodium (a derivative of Nedocromil) is reported as an ingredient of Tilarin in the following countries:
International Drug Name Search
Rec.INN
0000298-55-5
C26-H27-Cl-N2
402
Antihistaminic agent
1-(p-chloro-α-phenylbenzyl)-4-cinnamylpiperazine (WHO)
1-[(4-Chlorophenyl)phenylmethyl]-4-(3-phenyl-2-propenyl)piperazine
1-[(4-chlorophenyl)-phenylmethyl]-4-[(E)-3-phenylprop-2-enyl]piperazine (IUPAC)
1-Cinnamyl-4-(4-chlorobenzhydryl)piperazine
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| WHO | World Health Organization |
Pantoprazol Krka may be available in the countries listed below.
Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Pantoprazol Krka in the following countries:
International Drug Name Search
Po 12 may be available in the countries listed below.
Enoxolone is reported as an ingredient of Po 12 in the following countries:
International Drug Name Search
Curocef Inyectable may be available in the countries listed below.
Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Curocef Inyectable in the following countries:
International Drug Name Search
Thiocolchicoside Alter may be available in the countries listed below.
Thiocolchicoside is reported as an ingredient of Thiocolchicoside Alter in the following countries:
International Drug Name Search
Broncoliber may be available in the countries listed below.
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Broncoliber in the following countries:
International Drug Name Search
Citaratio may be available in the countries listed below.
Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Citaratio in the following countries:
International Drug Name Search
Alfadel may be available in the countries listed below.
Alfacalcidol is reported as an ingredient of Alfadel in the following countries:
International Drug Name Search
Pharcoba may be available in the countries listed below.
Cyanocobalamin is reported as an ingredient of Pharcoba in the following countries:
International Drug Name Search
Risedronate sodium 35 mg film-coated tablets.
One film-coated tablet contains 35 mg risedronate sodium which is equivalent to 32.5 mg risedronic acid.
Excipient: 1.9 mg lactose in each tablet. For a full list of excipients see section 6.1.
Film-coated tablet. White round biconvex film-coated tablet with diameter of 11.2 mm, 5.0 mm in thickness and embossed with “35” on one side.
Treatment of postmenopausal osteoporosis, to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures (see section 5.1).
Treatment of osteoporosis in men at high risk of fractures. (see section 5.1).
The recommended dose in adults is one 35 mg tablet orally once a week. The tablet should be taken on the same day each week. The absorption of risedronate sodium is affected by food, thus to ensure adequate absorption patients should take Risedronate:
• Before breakfast: At least 30 minutes before the first food, other medicinal product or drink (other than plain water) of the day.
Patients should be instructed that if a dose is missed, one Risedronate 35 mg tablet should be taken on the day that the tablet is remembered. Patients should then return to taking one tablet once a week on the day the tablet is normally taken. Two tablets should not be taken on the same day.
The tablet must be swallowed whole and not sucked or chewed. To aid delivery of the tablet to the stomach Risedronate is to be taken while in an upright (standing or sitting) position with a glass of plain water (
Supplemental calcium and vitamin D should be considered if the dietary intake is inadequate.
Elderly:
No dosage adjustment is necessary since bioavailability, distribution and elimination were similar in elderly (>60 years of age) compared to younger subjects. This has also been shown in the very elderly, 75 years old and above postmenopausal population.
Renal impairment:
No dosage adjustment is required for those patients with mild to moderate renal impairment. The use of risedronate sodium is contraindicated in patients with severe renal impairment (creatinine clearance lower than 30 ml/min) (see sections 4.3 and 5.2).
Children:
Safety and efficacy of risedronate 35 mg have not been established in children and adolescents.
Hypersensitivity to risedronate sodium or to any of the excipients.
Hypocalcaemia (see section 4.4).
Pregnancy and lactation.
Severe renal impairment (creatinine clearance <30ml/min).
Foods, drinks (other than plain water) and medicinal products containing polyvalent cations (such as calcium, magnesium, iron and aluminium) interfere with the absorption of bisphosphonates and should not be taken at the same time as Risedronate (see section 4.5). In order to achieve the intended efficacy, strict adherence to dosing recommendations is necessary (see section 4.2).
Efficacy of bisphosphonates in the treatment of osteoporosis is related to the presence of low bone mineral density and/or prevalent fracture.
High age or clinical risk factors for fracture alone are not sufficient reasons to initiate treatment of osteoporosis with a bisphosphonate.
The evidence to support efficacy of bisphosphonates including risedronate in the very elderly (>80 years) is limited (see section 5.1).
Bisphosphonates have been associated with oesophagitis, gastritis, oesophageal ulcerations and gastroduodenal ulcerations. Thus caution should be used:
• In patients who have a history of oesophageal disorders which delay oesophageal transit or emptying e.g. stricture or achalasia.
• In patients who are unable to stay in the upright position for at least 30 minutes after taking the tablet.
• If risedronate is given to patients with active or recent oesophageal or upper gastrointestinal problems.
Prescribers should emphasis to patients the importance of paying attention to the dosing instructions and be alert to any signs and symptoms of possible oesophageal reaction. The patients should be instructed to seek timely medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain or new/worsened heartburn.
Hypocalcaemia should be treated before starting Risedronate therapy. Other disturbances of bone and mineral metabolism (i.e. parathyroid dysfunction, hypovitaminosis D) should be treated at the time of starting Risedronate therapy.
Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelitis) has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphophonates. Many of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates.
A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, radiotherapy, corticosteroids, poor oral hygiene).
While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw.
Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit /risk assessment.
This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
No formal interaction studies have been performed, however no clinically relevant interactions with other medicinal products were found during clinical trials. In the risedronate sodium Phase III osteoporosis studies with daily dosing, acetylsalicylic acid or NSAID use was reported by 33% and 45% of patients respectively. In the Phase III once a week study in postmenopausal women, acetyl salicylic acid or NSAID use was reported by 57% and 40% of patients respectively. Among regular acetyl salicylic acid or NSAID users (3 or more days per week) the incidence of upper gastrointestinal adverse events in risedronate sodium treated patients was similar to that in control patients.
If considered appropriate risedronate sodium may be used concomitantly with oestrogen supplementation (for women only).
Concomitant ingestion of medications containing polyvalent cations (e.g. calcium, magnesium, iron and aluminium) will interfere with the absorption of Risedronate (see section 4.4).
Risedronate sodium is not systemically metabolised, does not induce cytochrome P450 enzymes, and has low protein binding.
There are no adequate data from the use of risedronate sodium in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Studies in animal indicate that a small amount of risedronate sodium pass into breast milk.
Risedronate sodium must not be used during pregnancy or by breast-feeding women.
No effects on ability to drive and use machines have been observed.
Risedronate sodium has been studied in phase III clinical trials involving more than 15,000 patients.
The majority of undesirable effects observed in clinical trials were mild to moderate in severity and usually did not require cessation of therapy.
Adverse experiences reported in phase III clinical trials in postmenopausal women with osteoporosis treated for up to 36 months with risedronate sodium 5mg/day (n=5020) or placebo (n=5048) and considered possibly or probably related to risedronate sodium are listed below using the following convention (incidences versus placebo are shown in brackets):
Very common (
Nervous system disorders:
Common: headache (1.8% vs. 1.4%)
Eye disorders:
Uncommon: iritis*
Gastrointestinal disorders:
Common: constipation (5.0% vs. 4.8%), dyspepsia (4.5% vs. 4.1%), nausea (4.3% vs. 4.0%), abdominal pain (3.5% vs. 3.3%), diarrhoea (3.0% vs. 2.7%)
Uncommon: gastritis (0.9% vs. 0.7%), oesophagitis (0.9% vs. 0.9%), dysphagia (0.4% vs. 0.2%), duodenitis (0.2% vs. 0.1%), oesophageal ulcer (0.2% vs. 0.2%)
Rare: glossitis (<0.1% vs. 0.1%), oesophageal stricture (<0.1% vs. 0.0%)
Musculoskeletal and connective tissues disorders:
Common: musculoskeletal pain (2.1% vs. 1.9%)
Investigations:
Rare: abnormal liver function tests*
* No relevant incidences from Phase III osteoporosis studies; frequency based on adverse event/laboratory/rechallenge findings in earlier clinical trials.
In a one-year, double-blind, multicentre study comparing risedronate sodium 5 mg daily (n=480) and risedronate sodium 35 mg weekly (n=485) in postmenopausal women with osteoporosis, the overall safety and tolerability profiles were similar. The following additional adverse experiences considered possibly or probably drug related by investigators have been reported (incidence greater in risedronate 35 mg than in risedronate sodium 5 mg group): gastrointestinal disorder (1.6% vs. 1.0%) and pain (1.2% vs. 0.8%).
In a 2-year study in men with osteoporosis, the overall safety and tolerability were similar between the treatment and the placebo groups. Adverse experiences were consistent with those previously observed in women.
Laboratory findings: Early, transient, asymptomatic and mild decreases in serum calcium and phosphate levels have been observed in some patients.
The following additional adverse reactions have been reported during post-marketing use (frequency unknown):
Eye disorders:
iritis, uveitis
Musculoskeletal and connective tissues disorders:
osteonecrosis of the jaw
Skin and subcutaneous tissue disorders:
hypersensitivity and skin reactions, including angioedema, generalised rash, urticaria, bullous skin reactions and leukocytoclastic vasculitis, some severe including isolated reports of Stevens Johnson syndrome and toxic epidermal necrolysis.
hair loss.
Immune system disorders:
anaphylactic reaction
Hepatobiliary disorders:
serious hepatic disorders. In most of the reported cases the patients were also treated with other products known to cause hepatic disorders.
No specific information is available on the treatment of overdose with risedronate sodium.
Decreases in serum calcium following substantial overdose may be expected. Signs and symptoms of hypocalcaemia may also occur in some of these patients.
Milk or antacids containing magnesium, calcium or aluminium should be given to bind risedronate and reduce absorption of risedronate sodium. In cases of substantial overdose, gastric lavage may be considered to remove unabsorbed risedronate sodium.
Pharmaco-therapeutic group: Bisphosphonates
ATC Code: M05 BA07.
Risedronate sodium is a pyridinyl bisphosphonate that binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption. The bone turnover is reduced while the osteoblast activity and bone mineralisation is preserved. In preclinical studies risedronate sodium demonstrated potent anti-osteoclast and antiresorptive activity, and dose dependently increased bone mass and biomechanical skeletal strength. The activity of risedronate sodium was confirmed by measuring biochemical markers for bone turnover during pharmacodynamic and clinical studies. In studies of post-menopausal women, decreases in biochemical markers of bone turnover were observed within 1 month and reached a maximum in 3-6 months. Decreases in biochemical markers of bone turnover were similar with Risedronate 35 mg once weekly and Risedronate 5 mg daily at 12 months.
In a study in men with osteoporosis, decreases in biochemical markers of bone turnover were observed at the earliest time point of 3 months and continued to be observed at 24 months.
Treatment of Postmenopausal Osteoporosis:
A number of risk factors are associated with postmenopausal osteoporosis including low bone mass, low bone mineral density, early menopause, a history of smoking and a family history of osteoporosis. The clinical consequence of osteoporosis is fractures. The risk of fractures is increased with the number of risk factors.
Based on effects on mean change in lumbar spine BMD, Risedronate 35 mg once wekly (n=485) was shown to be equivalent to Risedronate 5 mg daily (n=480) in a one-year, double-blind, multicentre study of postmenopausal women with osteoporosis.
The clinical programme for risedronate sodium administered once daily studied the effect of risedronate sodium on the risk of hip and vertebral fractures and contained early and late postmenopausal women with and without fracture. Daily doses of 2.5 mg and 5 mg were studied and all groups, including the control groups, received calcium and vitamin D (if baseline levels were low). The absolute and relative risk of new vertebral and hip fractures were estimated by use of a time-to-first event analysis.
• Two placebo-controlled trials (n=3.661) enrolled postmenopausal women under 85 years with vertebral fractures at baseline. Risedronate sodium 5 mg daily given for 3 years reduced the risk of new vertebral fractures relative to the control group.
In women with respectively at least 2 or at least 1 vertebral fracture, the relative risk reduction was 49% and 41% respectively (incidence of new vertebral fractures with risedronate sodium 18.1% and 11.3%, with placebo 29.0% and 16.3%, respectively). The effect of treatment was seen as early as the end of the first year of treatment. Benefits were also demonstrated in women with multiple fractures at baseline. Risedronate sodium 5 mg daily also reduced the yearly height loss compared to the control group.
• Two further placebo controlled trials enrolled postmenopausal women above 70 years with or without vertebral fractures at baseline. Women 70-79 years were enrolled with femoral neck BMD T-score < -3 SD (manufacturer's range, i.e. -2.5 SD using NHANES III) and at least one additional risk factor. Women a-posteriori analysis of subgroups defined by clinical practise and current definitions of osteoporosis:
- In the subgroup of patients with femoral neck BMD T-score <-2.5SD (NHANES III) and at least one vertebral fracture at baseline, risedronate sodium given for 3 years reduced the risk of hip fractures by 46% relative to the control group (Incidence of hip fractures in combined risedronate sodium 2.5 mg and 5 mg groups were 3.8%, placebo 7.4%).
- Data suggest that a more limited protection than this may be observed in the very elderly (>80 years). This may be due to the increasing importance of non-skeletal factors for hip fracture with increasing age. In these trials, data analysed as a secondary endpoint indicated a decrease in the risk of new vertebral fractures in patients with low femoral neck BMD without vertebral fracture and in patients with low femoral neck BMD with or without vertebral fracture.
• Risedronate sodium 5 mg daily given for 3 years increased bone mineral density (BMD) relative to control at the lumbar spine, femoral neck, trochanter and wrist and maintained bone density at the mid-shaft radius.
• In a one-year follow-up off therapy after three years treatment with risedronate sodium 5 mg daily there was rapid reversibility of the suppressing effect of risedronate sodium on bone turnover rate.
• Bone biopsy samples from postmenopausal women treated with risedronate sodium 5 mg daily for 2 to 3 years, showed an expected moderate decrease in bone turnover. Bone formed during risedronate sodium treatment was of normal lamellar structure and bone mineralisation. These data together with the decreased incidence of osteoporosis related fractures at vertebral sites in women with osteoporosis appear to indicate no detrimental effect on bone quality.
Endoscopic findings from a number of patients with a number of moderate to severe gastrointestinal complaints in both risedronate sodium and control patients indicated no evidence of treatment related gastric, duodenal or oesophageal ulcers in either group, although duodenitis was uncommonly observed in the risedronate sodium group.
Treatment of Osteoporosis in Men
Risedronate sodium 35mg once a week demonstrated efficacy in men with osteoporosis (age range 36 to 84 years) in a 2-year, double-blind, placebo-controlled study in 284 patients (risedronate sodium 35mg, n = 191). All patients received supplemental calcium and vitamin D.
Increases in BMD were observed as early as 6 months following initiation of risedronate sodium treatment. Risedronate sodium 35mg once a week produced mean increases in BMD at the lumbar spine, femoral neck, trochanter and total hip compared to placebo after 2 years of treatment. Antifracture efficacy was not demonstrated in this study.
The bone effect (BMD increase and BTM decrease) of risedronate sodium is similar in males and females.
Absorption: Absorption after an oral dose is relatively rapid (tmax ~1 hour) and is independent of dose over the range studied (single dose study, 2.5 to 30 mg; multiple dose studies, 2.5 to 5 mg daily and up to 50 mg dosed weekly). Mean oral bioavailability of the tablet is 0.63% and is decreased when risedronate sodium is administered with food. Bioavailability was similar in men and women.
Distribution: The mean steady state volume of distribution is 6.3 l/kg in humans.
Plasma protein binding is about 24%.
Metabolism: There is no evidence of systemic metabolism of risedronate sodium.
Elimination: Approximately half of the absorbed dose is excreted in urine within 24 hours, and 85% of an intravenous dose is recovered in the urine after 28 days. Mean renal clearance is 105 ml/min and mean total clearance is 122 ml/min, with the difference probably attributed to clearance due to adsorption to bone. The renal clearance is not concentration dependent, and there is a linear relationship between renal clearance and creatinine clearance. Unabsorbed risedronate sodium is eliminated unchanged in faeces. After oral administration the concentration-time profile shows three elimination phases with a terminal half-life of 480 hours.
Special Populations
Elderly: no dosage adjustment is necessary.
Acetylsalicylic acid/NSAID users: Among regular acetyl salicylic acid or NSAID users (3 or more days per week) the incidence of upper gastrointestinal adverse events in risedronate sodium treated patients was similar to that in control patients.
In toxicological studies in rat and dog dose dependent liver toxic effects of risedronate sodium were seen, primarily as enzyme increases with histological changes in rat. The clinical relevance of these observations is unknown. Testicular toxicity occurred in rat and dog at exposures considered in excess of the human therapeutic exposure. Dose related incidences of upper airway irritation were frequently noted in rodents. Similar effects have been seen with other bisphosphonates. Lower respiratory tract effects were also seen in longer term studies in rodents, although the clinical significance of these findings is unclear. In reproduction toxicity studies at exposures close to clinical exposure ossification changes were seen in sternum and/or skull of foetuses from treated rats and hypocalcaemia and mortality in pregnant females allowed to deliver. There was no evidence of teratogenesis at 3.2mg/kg/day in rat and 10mg/kg/day in rabbit, although data are only available on a small number of rabbits. Maternal toxicity prevented testing of higher doses. Studies on genotoxicity and carcinogenesis did not show any particular risks for humans.
Tablet core:
Starch, pregelatinised (maize); Cellulose, microcrystalline; Crospovidone; Magnesium stearate.
Film coating:
Hypromellose; Lactose monohydrate; Titanium dioxide (E171); Macrogol 4000.
Not applicable.
3 years.
This medicinal product does not require any special storage conditions.
Nature of container: Opaque PVC/PE/PVDC/Aluminium blister in a carton box.
Pack sizes: 1, 2, 4, 10, 12, 16 tablets
Not all pack sizes may be marketed.
No special requirements.
Beacon Pharmaceuticals Ltd., 85 High St., Tunbridge Wells, TN1 1YG. UK.
PL 18157/0235
03/08/2010
03/08/2010
Bicarbonate de Sodium Lavoisier may be available in the countries listed below.
Sodium Bicarbonate is reported as an ingredient of Bicarbonate de Sodium Lavoisier in the following countries:
International Drug Name Search
P-PPI may be available in the countries listed below.
Pantoprazole is reported as an ingredient of P-PPI in the following countries:
International Drug Name Search
Hypace may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Hypace in the following countries:
Ramipril is reported as an ingredient of Hypace in the following countries:
International Drug Name Search
Terloc may be available in the countries listed below.
Amlodipine is reported as an ingredient of Terloc in the following countries:
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Terloc in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Chorionic Gonadotrophin is reported as an ingredient of Chortropin in the following countries:
International Drug Name Search
Minoxidil is reported as an ingredient of Theroxidil in the following countries:
International Drug Name Search
Lilly-Fluoxetine may be available in the countries listed below.
Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Lilly-Fluoxetine in the following countries:
International Drug Name Search
Absolute Drench may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Abamectin is reported as an ingredient of Absolute Drench in the following countries:
Sodium Selenate is reported as an ingredient of Absolute Drench in the following countries:
International Drug Name Search
Elplat may be available in the countries listed below.
Oxaliplatin is reported as an ingredient of Elplat in the following countries:
International Drug Name Search
Insulatard HM Penfil may be available in the countries listed below.
Insulin, Isophane human (a derivative of Insulin, Isophane) is reported as an ingredient of Insulatard HM Penfil in the following countries:
International Drug Name Search
Grifotenol may be available in the countries listed below.
Atenolol is reported as an ingredient of Grifotenol in the following countries:
International Drug Name Search
Bupiforan may be available in the countries listed below.
Bupivacaine hydrochloride (a derivative of Bupivacaine) is reported as an ingredient of Bupiforan in the following countries:
International Drug Name Search
Bufetolol Hydrochloride may be available in the countries listed below.
Bufetolol Hydrochloride (JAN) is also known as Bufetolol (Rec.INN)
International Drug Name Search
Glossary
| JAN | Japanese Accepted Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Rostil may be available in the countries listed below.
Mebeverine hydrochloride (a derivative of Mebeverine) is reported as an ingredient of Rostil in the following countries:
International Drug Name Search
Furamebe may be available in the countries listed below.
Diloxanide ester with 2-furoic acid (a derivative of Diloxanide) is reported as an ingredient of Furamebe in the following countries:
International Drug Name Search
Lonet may be available in the countries listed below.
Atenolol is reported as an ingredient of Lonet in the following countries:
International Drug Name Search
Algon may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Metamizole sodium anhydrous (a derivative of Metamizole) is reported as an ingredient of Algon in the following countries:
International Drug Name Search
Acetylcysteine Mylan may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of Acetylcysteine Mylan in the following countries:
International Drug Name Search
Fénofibrate Sandoz may be available in the countries listed below.
Fenofibrate is reported as an ingredient of Fénofibrate Sandoz in the following countries:
International Drug Name Search
Cox B1 may be available in the countries listed below.
Thiamine hydrochloride (a derivative of Thiamine) is reported as an ingredient of Cox B1 in the following countries:
International Drug Name Search
Clindana may be available in the countries listed below.
Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Clindana in the following countries:
International Drug Name Search
Eficur may be available in the countries listed below.
Ceftiofur hydrochloride (a derivative of Ceftiofur) is reported as an ingredient of Eficur in the following countries:
International Drug Name Search
Lamimac may be available in the countries listed below.
Lamivudine is reported as an ingredient of Lamimac in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Moxidectin is reported as an ingredient of Exodus in the following countries:
Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Exodus in the following countries:
Selenium is reported as an ingredient of Exodus in the following countries:
International Drug Name Search
Losar-Q comp. may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Losar-Q comp. in the following countries:
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losar-Q comp. in the following countries:
International Drug Name Search
Momate may be available in the countries listed below.
Mometasone 17-(2-furoate) (a derivative of Mometasone) is reported as an ingredient of Momate in the following countries:
International Drug Name Search
Renul may be available in the countries listed below.
Ranitidine is reported as an ingredient of Renul in the following countries:
International Drug Name Search
Furosemida Genfarma may be available in the countries listed below.
Furosemide is reported as an ingredient of Furosemida Genfarma in the following countries:
International Drug Name Search
Gastrast K may be available in the countries listed below.
Sodium Bicarbonate is reported as an ingredient of Gastrast K in the following countries:
International Drug Name Search
Beloc-Zok comp may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Beloc-Zok comp in the following countries:
Metoprolol succinate (a derivative of Metoprolol) is reported as an ingredient of Beloc-Zok comp in the following countries:
International Drug Name Search
Carrashimease may be available in the countries listed below.
Tilactase is reported as an ingredient of Carrashimease in the following countries:
International Drug Name Search
Albiotic may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Lincomycin hydrochloride monohydrate (a derivative of Lincomycin) is reported as an ingredient of Albiotic in the following countries:
International Drug Name Search
Tobirax may be available in the countries listed below.
Tobramycin sulfate (a derivative of Tobramycin) is reported as an ingredient of Tobirax in the following countries:
International Drug Name Search
Amlodipine Actavis may be available in the countries listed below.
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Amlodipine Actavis in the following countries:
International Drug Name Search
Capterenol may be available in the countries listed below.
Procaterol hydrochloride hemihydrate (a derivative of Procaterol) is reported as an ingredient of Capterenol in the following countries:
International Drug Name Search
Indometacin Helvepharm may be available in the countries listed below.
Indometacin is reported as an ingredient of Indometacin Helvepharm in the following countries:
International Drug Name Search
Arrow Alprazolam may be available in the countries listed below.
Alprazolam is reported as an ingredient of Arrow Alprazolam in the following countries:
International Drug Name Search
Espirone may be available in the countries listed below.
Spironolactone is reported as an ingredient of Espirone in the following countries:
International Drug Name Search
Pepcidin may be available in the countries listed below.
Famotidine is reported as an ingredient of Pepcidin in the following countries:
International Drug Name Search
Fluoxetina La Santé may be available in the countries listed below.
Fluoxetine is reported as an ingredient of Fluoxetina La Santé in the following countries:
International Drug Name Search
Métergoline may be available in the countries listed below.
Métergoline (DCF) is also known as Metergoline (Rec.INN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Fulruban may be available in the countries listed below.
Flurbiprofen is reported as an ingredient of Fulruban in the following countries:
International Drug Name Search
Ramipril comp. Heumann may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Ramipril comp. Heumann in the following countries:
Ramipril is reported as an ingredient of Ramipril comp. Heumann in the following countries:
International Drug Name Search
Jonctum may be available in the countries listed below.
Oxaceprol is reported as an ingredient of Jonctum in the following countries:
International Drug Name Search
Bicavan may be available in the countries listed below.
Bicalutamide is reported as an ingredient of Bicavan in the following countries:
International Drug Name Search
Co Diovan Forte may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Co Diovan Forte in the following countries:
Valsartan is reported as an ingredient of Co Diovan Forte in the following countries:
International Drug Name Search
Cefradina L.CH. may be available in the countries listed below.
Cefradine is reported as an ingredient of Cefradina L.CH. in the following countries:
International Drug Name Search
Budesonid-ratiopharm may be available in the countries listed below.
Budesonide is reported as an ingredient of Budesonid-ratiopharm in the following countries:
International Drug Name Search
Mucodyne Paediatric may be available in the countries listed below.
Carbocisteine is reported as an ingredient of Mucodyne Paediatric in the following countries:
International Drug Name Search
Rec.INN
0047739-98-0
C28-H37-Cl-N4-O
481
Neuroleptic
[1,4'-Bipiperidine]-4'-carboxamide, 1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]-
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Captopril TV may be available in the countries listed below.
Captopril is reported as an ingredient of Captopril TV in the following countries:
International Drug Name Search
Flihaler may be available in the countries listed below.
Fluticasone propionate (a derivative of Fluticasone) is reported as an ingredient of Flihaler in the following countries:
International Drug Name Search
Aurofox may be available in the countries listed below.
Ceftriaxone disodium salt (a derivative of Ceftriaxone) is reported as an ingredient of Aurofox in the following countries:
International Drug Name Search
Prednisonal may be available in the countries listed below.
Meprednisone is reported as an ingredient of Prednisonal in the following countries:
International Drug Name Search
Crisomet may be available in the countries listed below.
Lamotrigine is reported as an ingredient of Crisomet in the following countries:
International Drug Name Search
Bonmax may be available in the countries listed below.
Raloxifene hydrochloride (a derivative of Raloxifene) is reported as an ingredient of Bonmax in the following countries:
International Drug Name Search
Morphin AL may be available in the countries listed below.
Morphine sulphate pentahydrate (a derivative of Morphine) is reported as an ingredient of Morphin AL in the following countries:
International Drug Name Search
Magicul may be available in the countries listed below.
Cimetidine is reported as an ingredient of Magicul in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Pyrantel tartrate (a derivative of Pyrantel) is reported as an ingredient of Ban A Worm in the following countries:
International Drug Name Search
Amoxicilline may be available in the countries listed below.
Amoxicilline (DCF) is known as Amoxicillin in the US.
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
Mebhydrolin Napadisilate may be available in the countries listed below.
Mebhydrolin Napadisilate (BANM) is also known as Mebhydrolin (Rec.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Mecir may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Mecir in the following countries:
International Drug Name Search
Kratalgin may be available in the countries listed below.
Ibuprofen is reported as an ingredient of Kratalgin in the following countries:
International Drug Name Search
Flucanol may be available in the countries listed below.
Fluconazole is reported as an ingredient of Flucanol in the following countries:
International Drug Name Search
Fosagen may be available in the countries listed below.
Alendronic Acid is reported as an ingredient of Fosagen in the following countries:
International Drug Name Search
Kaprogest may be available in the countries listed below.
Hydroxyprogesterone caproate (a derivative of Hydroxyprogesterone) is reported as an ingredient of Kaprogest in the following countries:
International Drug Name Search
Cantharides Tincture may be available in the countries listed below.
Cantharidin is reported as an ingredient of Cantharides Tincture in the following countries:
International Drug Name Search
Metocarbamolo may be available in the countries listed below.
Metocarbamolo (DCIT) is known as Methocarbamol in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Ceftriaxone Biopharma may be available in the countries listed below.
Ceftriaxone disodium salt (a derivative of Ceftriaxone) is reported as an ingredient of Ceftriaxone Biopharma in the following countries:
International Drug Name Search
Binaldan may be available in the countries listed below.
Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Binaldan in the following countries:
International Drug Name Search
Frakidex may be available in the countries listed below.
Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Frakidex in the following countries:
Framycetin sulfate (a derivative of Framycetin) is reported as an ingredient of Frakidex in the following countries:
International Drug Name Search
Metoprolol-Acino Succ may be available in the countries listed below.
Metoprolol succinate and tartrate (a derivative of Metoprolol) is reported as an ingredient of Metoprolol-Acino Succ in the following countries:
International Drug Name Search
Pipéridolate may be available in the countries listed below.
Pipéridolate (DCF) is also known as Piperidolate (Rec.INN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Genesis Drench with Selenium may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ivermectin is reported as an ingredient of Genesis Drench with Selenium in the following countries:
Sodium Selenate is reported as an ingredient of Genesis Drench with Selenium in the following countries:
International Drug Name Search
In the US, Bidil (hydralazine/isosorbide dinitrate systemic) is a member of the drug class antihypertensive combinations and is used to treat Heart Failure.
US matches:
Hydralazine hydrochloride (a derivative of Hydralazine) is reported as an ingredient of Bidil in the following countries:
Isosorbide Dinitrate is reported as an ingredient of Bidil in the following countries:
International Drug Name Search
Evalen may be available in the countries listed below.
Adapalene is reported as an ingredient of Evalen in the following countries:
International Drug Name Search
Gentamicina + Beclometasone DOC may be available in the countries listed below.
Beclometasone 17α,21-dipropionate (a derivative of Beclometasone) is reported as an ingredient of Gentamicina + Beclometasone DOC in the following countries:
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Gentamicina + Beclometasone DOC in the following countries:
International Drug Name Search
Ciclosporin Hexal may be available in the countries listed below.
Ciclosporin is reported as an ingredient of Ciclosporin Hexal in the following countries:
International Drug Name Search
Paroxetina Arrowblue may be available in the countries listed below.
Paroxetine is reported as an ingredient of Paroxetina Arrowblue in the following countries:
International Drug Name Search
PMS-Pravastatin may be available in the countries listed below.
Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of PMS-Pravastatin in the following countries:
International Drug Name Search
Fucithalmic may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
UK matches:
Fusidic Acid is reported as an ingredient of Fucithalmic in the following countries:
Fusidic Acid hemihydrate (a derivative of Fusidic Acid) is reported as an ingredient of Fucithalmic in the following countries:
International Drug Name Search
Clomipramine HCl Merck may be available in the countries listed below.
Clomipramine hydrochloride (a derivative of Clomipramine) is reported as an ingredient of Clomipramine HCl Merck in the following countries:
International Drug Name Search
Mitomicina C Filaxis may be available in the countries listed below.
Mitomycin is reported as an ingredient of Mitomicina C Filaxis in the following countries:
International Drug Name Search
Fluometholone may be available in the countries listed below.
Fluorometholone is reported as an ingredient of Fluometholone in the following countries:
International Drug Name Search
Xerenex may be available in the countries listed below.
Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Xerenex in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Chorionic Gonadotrophin is reported as an ingredient of Chlorulon in the following countries:
International Drug Name Search
Elotaxin may be available in the countries listed below.
Oxaliplatin is reported as an ingredient of Elotaxin in the following countries:
International Drug Name Search
Xylazil may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Xylazine hydrochloride (a derivative of Xylazine) is reported as an ingredient of Xylazil in the following countries:
International Drug Name Search
Motidom may be available in the countries listed below.
Domperidone is reported as an ingredient of Motidom in the following countries:
International Drug Name Search
In the US, Gliadel (carmustine systemic) is a member of the drug class alkylating agents and is used to treat Brain Tumor, Glioblastoma Multiforme, Hodgkin's Lymphoma, Malignant Glioma, Multiple Myeloma and Non-Hodgkin's Lymphoma.
US matches:
UK matches:
Carmustine is reported as an ingredient of Gliadel in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Modavigil may be available in the countries listed below.
Modafinil is reported as an ingredient of Modavigil in the following countries:
International Drug Name Search
